Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00733590 |
|
Recruitment Status :
Recruiting
First Posted : August 13, 2008
Last Update Posted : August 16, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pulse generator replacement for primary prevention of SCD (PROSe-ICD) was established to :
- to gain a better understanding of the biological mechanisms that predispose to SCD
- to develop readily determined clinical, electrocardiographic, genetic and blood protein markers identify patients with an increased risk of dying suddenly
| Condition or disease |
|---|
| Heart Failure, Congestive Death, Sudden, Cardiac Arrhythmia Cardiomyopathies |
Show Detailed Description
| Study Type : | Observational |
| Estimated Enrollment : | 1500 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD) |
| Actual Study Start Date : | June 2003 |
| Estimated Primary Completion Date : | March 2020 |
| Estimated Study Completion Date : | March 2020 |
- Arrhythmic Sudden Death defined as a therapy from the ICD for rapid VT or VF or a ventricular arrhythmia not corrected by the ICD [ Time Frame: 10 years ]
- All cause mortality, CV mortality, heart transplant, LVAD, and ICD explantation or ICD Disabled [ Time Frame: Total period of observation in the study ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- History of acute MI at least 4 weeks old
- Non-ischemic LV dysfunction for at least 9 months
- Who have an EF < or = to 35%
- Undergone first ERI generator replacement of an FDA-approved ICD for primary prevention of SCD within 12 months of enrollment
Exclusion Criteria:
- ICD generator replacement for secondary prevention
- Inability or unwillingness to provide valid informed consent
- New York Heart Association Class IV heart failure
- Patients with pre-existing Class 1 indications for pacemaker therapy.
- CRT-D devices.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733590
| Contact: Barbara Butcher, BSN | 443 287-3472 | bbutche1@jhmi.edu |
| United States, District of Columbia | |
| Washington Hospital Center | Recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: Zayd Eldadah, MD, PhD 202-877-7865 Zayd.Eldadah@Medstar.Net | |
| United States, Maryland | |
| University of Maryland Medical Center | Recruiting |
| Baltimore, Maryland, United States, 21201 | |
| Contact: Stephen R Shorofsky, MD, PhD 800-492-5538 Sshorofs@medicine.umaryland.edu | |
| Johns Hopkins University School of Medicine | Recruiting |
| Baltimore, Maryland, United States, 21205 | |
| Contact: Barbara Butcher, BSN 443-287-3472 bbutche1@jhmi.edu | |
| Contact: Gordon Tomaselli, MD 410 955-2774 gtomasel@jhmi.edu | |
| United States, Virginia | |
| Virginia Commonwealth University School of Medicine | Recruiting |
| Richmond, Virginia, United States, 23298 | |
| Contact: Kenneth Ellenbogen, MD 804-828-7576 kellenbogen@pol.net | |
| Principal Investigator: | Gordon F Tomaselli, MD | Professor of Medicine Johns Hopkins University |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT00733590 History of Changes |
| Other Study ID Numbers: |
NA_00045142 5R01HL091062 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 13, 2008 Key Record Dates |
| Last Update Posted: | August 16, 2018 |
| Last Verified: | August 2018 |
Keywords provided by Johns Hopkins University:
|
defibrillator, implanted genomics electrocardiography electrophysiological study proteomics |
Additional relevant MeSH terms:
|
Heart Failure Cardiomyopathies Death Death, Sudden, Cardiac Death, Sudden |
Heart Diseases Cardiovascular Diseases Pathologic Processes Heart Arrest |